Biography

Prof. Dr. Alireza Heidari

Faculty of Chemistry

California South University (CSU), California, USA

Full Professor


Emails: Scholar.Researcher.Scientist@gmail.com (preferred), Alireza.Heidari@calsu.us


Qualifications

2012 Ph.D., California South University, USA

2008 M.S., Islamic Azad University (IAU), Iran

2005 B.S., Islamic Azad University (IAU), Iran


Research Fields

Nanochemistry

Molecular Modelling

Synchrotron Radiation

Anti–Cancer Nano Drugs

Nano Drugs Delivery


Publications (selected)

  1. A. Heidari, C. Brown, “Study of Composition and Morphology of Cadmium Oxide (CdO) Nanoparticles for Eliminating Cancer Cells”, Journal of Nanomedicine Research, Volume 2, Issue 5, 20 Pages, 2015.
  2. A. Heidari, C. Brown, “Study of Surface Morphological, Phytochemical and Structural Characteristics of Rhodium (III) Oxide (Rh2O3) Nanoparticles”, International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Volume 1, Pages 15–19, 2015.
  3. A. Heidari, “Computational Studies on Molecular Structures and Carbonyl and Ketene Groups’ Effects of Singlet and Triplet Energies of Azidoketene O=C=CH–NNN and Isocyanatoketene O=C=CH–N=C=O”, J Appl Computat Math 5: e142, 2016.
  4. A. Heidari, “Study of Irradiations to Enhance the Induces the Dissociation of Hydrogen Bonds between Peptide Chains and Transition from Helix Structure to Random Coil Structure Using ATR–FTIR, Raman and 1HNMR Spectroscopies”, J Biomol Res Ther 5: e146, 2016.
  5. A. Heidari, “Future Prospects of Point Fluorescence Spectroscopy, Fluorescence Imaging and Fluorescence Endoscopy in Photodynamic Therapy (PDT) for Cancer Cells”, J Bioanal Biomed 8: e135, 2016.
  6. A. Heidari, “Quantitative Structure–Activity Relationship (QSAR) Approximation for Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh2O3) Nanoparticles as Anti–Cancer Drugs for the Catalytic Formation of Proviral DNA from Viral RNA Using Multiple Linear and Non–Linear Correlation Approach”, Ann Clin Lab Res. 4: 1, 2016.
  7. A. Heidari, “Spectroscopy and Quantum Mechanics of the Helium Dimer (He2+), Neon Dimer (Ne2+), Argon Dimer (Ar2+), Krypton Dimer (Kr2+), Xenon Dimer (Xe2+), Radon Dimer(Rn2+) and Ununoctium Dimer (Uuo2+) Molecular Cations”, Chem Sci J 7: e112, 2016.
  8. A. Heidari, “A Combined Computational and QM/MM Molecular Dynamics Study on Boron Nitride Nanotubes (BNNTs), Amorphous Boron Nitride Nanotubes (a–BNNTs) and Hexagonal Boron Nitride Nanotubes (h–BNNTs) as Hydrogen Storage”, Struct Chem Crystallogr Commun 2: 1, 2016.
  9. A. Heidari, “Combined Theoretical and Computational Study of the Belousov–Zhabotinsky Chaotic Reaction and Curtius Rearrangement for Synthesis of Mechlorethamine, Cisplatin, Streptozotocin, Cyclophosphamide, Melphalan, Busulphan and BCNU as Anti–Cancer Drugs”, Insights Med Phys. 1: 2, 2016.
  10. A. Heidari, “Ab Initio and Density Functional Theory (DFT) Studies of Dynamic NMR Shielding Tensors and Vibrational Frequencies of DNA/RNA and Cadmium Oxide (CdO) Nanoparticles Complexes in Human Cancer Cells”, J Nanomedine Biotherapeutic Discov 6: e144, 2016.
  11. A. Heidari, “Molecular Dynamics and Monte–Carlo Simulations for Replacement Sugars in Insulin Resistance, Obesity, LDL Cholesterol, Triglycerides, Metabolic Syndrome, Type 2 Diabetes and Cardiovascular Disease: A Glycobiological Study”, J Glycobiol 5: e111, 2016.
  12. A. Heidari, “Nitrogen, Oxygen, Phosphorus and Sulphur Heterocyclic Anti–Cancer Nano Drugs Separation in the Supercritical Fluid of Ozone (O3) Using Soave–Redlich–Kwong (SRK) and Pang–Robinson (PR) Equations”, Electronic J Biol 12: 4, 2016.
  13. A. Heidari, “An Analytical and Computational Infrared Spectroscopic Review of Vibrational Modes in Nucleic Acids”, Austin J Anal Pharm Chem. 3(1): 1058, 2016.
  14. A. Heidari, C. Brown, “Phase, Composition and Morphology Study and Analysis of Os–Pd/HfC Nanocomposites”, Nano Res Appl. 2: 1, 2016.
  15. A. Heidari, C. Brown, “Vibrational Spectroscopic Study of Intensities and Shifts of Symmetric Vibration Modes of Ozone Diluted by Cumene”, International Journal of Advanced Chemistry, 4 (1) 5–9, 2016.
  16. A. Heidari, “Linear and Non–Linear Quantitative Structure–Anti–Cancer–Activity Relationship (QSACAR) Study of Hydrous Ruthenium (IV) Oxide (RuO2) Nanoparticles as Non–Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Anti–Cancer Nano Drugs”, J Integr Oncol 5: e110, 2016.
  17. A. Heidari, “A Pharmacovigilance Study on Linear and Non–Linear Quantitative Structure (Chromatographic) Retention Relationships (QSRR) Models for the Prediction of Retention Time of Anti–Cancer Nano Drugs under Synchrotron Radiations”, J Pharmacovigil 4: e161, 2016.
  18. A. Heidari, “A Gastrointestinal Study on Linear and Non–Linear Quantitative Structure (Chromatographic) Retention Relationships (QSRR) Models for Analysis 5–Aminosalicylates Nano Particles as Digestive System Nano Drugs under Synchrotron Radiations”, J Gastrointest Dig Syst 6: e119, 2016.
  19. A. Heidari, “A Successful Strategy for the Prediction of Solubility in the Construction of Quantitative Structure–Activity Relationship (QSAR) and Quantitative Structure–Property Relationship (QSPR) under Synchrotron Radiations Using Genetic Function Approximation (GFA) Algorithm”, J Mol Biol Biotechnol 1: 1, 2016.
  20. A. Heidari, “Computational Study on Molecular Structures of C20, C60, C240, C540, C960, C2160 and C3840 Fullerene Nano Molecules under Synchrotron Radiations Using Fuzzy Logic”, J Material Sci Eng 5: 282, 2016.
  21. A. Heidari, “Graph Theoretical Analysis of Zigzag Polyhexamethylene Biguanide, Polyhexamethylene Adipamide, Polyhexamethylene Biguanide Gauze and Polyhexamethylene Biguanide Hydrochloride (PHMB) Boron Nitride Nanotubes (BNNTs), Amorphous Boron Nitride Nanotubes (a–BNNTs) and Hexagonal Boron Nitride Nanotubes (h–BNNTs)”, J Appl Computat Math 5: e143, 2016.
  22. A. Heidari, “Yoctosecond Quantitative Structure–Activity Relationship (QSAR) and Quantitative Structure–Property Relationship (QSPR) under Synchrotron Radiations Studies for Prediction of Solubility of Anti–Cancer Nano Drugs in Aqueous Solutions Using Genetic Function Approximation (GFA) Algorithm”, Insight Pharm Res. 1: 1, 2016.
  23. A. Heidari, “Polymorphism in Nano–Sized Graphene Ligand–Induced Transformation of Au38–xAgx/xCux(SPh–tBu)24 to Au36–xAgx/xCux(SPh–tBu)24 (x = 1–12) Nanomolecules for Synthesis of Au144–xAgx/xCux[(SR)60, (SC4)60, (SC6)60, (SC12)60, (PET)60, (p–MBA)60, (F)60, (Cl)60, (Br)60, (I)60, (At)60, (Uus)60 and (SC6H13)60] Nano Clusters as Anti–Cancer Nano Drugs”, J Nanomater Mol Nanotechnol, 6: 3, 2017.
  24. A. Heidari, “Study of Synthesis, Pharmacokinetics, Pharmacodynamics, Dosing, Stability, Safety and Efficacy of Olympiadane Nanomolecules as Agent for Cancer Enzymotherapy, Immunotherapy, Chemotherapy, Radiotherapy, Hormone Therapy and Targeted Therapy under Synchrotorn Radiation”, J Dev Drugs 6: e154.
  25. A. Heidari, “Concurrent Diagnosis of Oncology Influence Outcomes in Emergency General Surgery for Colorectal Cancer and Multiple Sclerosis (MS) Treatment Using Magnetic Resonance Imaging (MRI) and Au329(SR)84, Au329–xAgx(SR)84, Au144(SR)60, Au68(SR)36, Au30(SR)18, Au102(SPh)44, Au38(SPh)24, Au38(SC2H4Ph)24, Au21S(SAdm)15, Au36(pMBA)24 and Au25(pMBA)18 Nano Clusters”, J Surgery Emerg Med 1: 21, 2017.


Profile Details

http://calsu.us/index.php/member/prof-dr-alireza-heidari/


Last Updated: 2017-07-16

Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top